Showing 271-280 of 1699 results for "".
- In Memoriam: Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANAhttps://practicalneurology.com/news/in-memoriam-martin-a-samuels-md-dsc-hon-faan-macp-frcp-fana/2470226/Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANA, the first named Miriam Sydney Joseph Distinguished Professor of Neurology at Harvard Medical School, passed away on June 6, 2023, at age 77.
- 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research Presented to Lars Lannfelt, MD, PhDhttps://practicalneurology.com/news/2024-lifetime-achievement-award-in-alzheimers-disease-therapeutic-research-presented-to-lars-lannfelt-md-phd/2470618/Lars Lannfelt, MD, PhD has been recognized as the recipient of the 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference. Dr. Lannfelt was selected based on his pioneering work in Alzheim
- UCSF Professor Bruce Ovbiagele, MD Recognized with Scientific Breakthrough Award at AAN 2024https://practicalneurology.com/news/ucsf-professor-bruce-ovbiagele-md-recognized-with-scientific-breakthrough-award-at-aan-2024/2470442/This year, the American Brain Foundation (ABF) awarded Bruce Ovbiagele, MD, MAS, FAAN the annual Scientific Breakthrough Award. Dr Ovbiagele, a Professor of Neurology at University of California (UC) San Francisco and Associate Dean of the San Francisco Veterans Affairs (VA) Healthcare Syste
- Possible Treatment for Focal Laryngeal Dystonia Revealed at MDS Conferencehttps://practicalneurology.com/news/possible-treatment-for-focal-laryngeal-dystonia-reported-at-mds-conference/2470597/Results of a double-blind, placebo-controlled, randomized cross-over study presented at the 2024 International Congress of Parkinson’s Disease and Movement Disorders suggest that sodium oxybate (SO) may be an effective treatment for some people with focal laryngeal dystonia (LD). This phase
- In Memoriam: Ralph L. Sacco, MD, MS, FAHA, FAANhttps://practicalneurology.com/news/in-memoriam-ralph-l-sacco-md-ms-faha-faan/2470102/
- Barancik Prize Awarded to Dr. Ruth Ann Marrie at ACTRIMS 2023https://practicalneurology.com/news/barancik-prize-awarded-to-dr-ruth-ann-marrie-at-actrims-2023/2470120/The National Multiple Sclerosis Society announced that Ruth Ann Marrie, MD, P
- Fenfluramine May Usher in Higher Standards for Treatment of Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-may-usher-in-higher-standards-for-treatment-of-dravet-syndrome/2469642/In an editorial in Epilepsy and Behavior, Helen Cross, MD and Joseph Sullivan, MD suggest fenfluramine (Fintepla; Zogenix, Emeryville, CA) clinical trial results can raise the bar for efficacy of antiseizure medications (ASMs) for
- Award Recipients Recognized at the 2024 International Congress of Parkinson’s Disease and Movement Disordershttps://practicalneurology.com/news/award-recipients-recognized-at-the-2024-international-congress-of-parkinsons-disease-and-movement-disorders/2470598/The International Parkinson’s Disease and Movement Disorders Society (MDS) has announced recipients of the 2024 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The
- FDA Approves Mirabegron for Neurogenic Detrusor Overactivity in Pediatric Patientshttps://practicalneurology.com/news/fda-approves-mirabegron-for-neurogenic-detrusor-overactivity-in-pediatric-patients/2469543/The Food and Drug Administration approved a new indication for mirabegron extended-release tablets (Myrbetriq; Silver Spring, MD) and mirabegron for extended-release oral suspension (Myrbetriq Granules; Silver Spring, MD) to treat neurogenic detrusor overactivity (NDO) in children age 3 yea
- Vamorolone Has Efficacy for Treating Duchenne Muscular Dystrophy Without Affecting Growthhttps://practicalneurology.com/news/vamorolone-has-efficacy-for-treating-duchenne-muscular-dystrophy-without-affecting-growth/2470013/In the VISION-DMD trial (NCT02760277), children with Duchenne muscular dystrophy (DMD) treated with vamorolone (ReveraGen BioPharma, Rockville, MD), had improved motor function with no negative effects on linear growth or biomarkers of